当前位置: 首页 >> 检索结果
共有 62504 条符合本次的查询结果, 用时 2.411655 秒

1261. Validity and Accuracy of the Derived Left Ventricular End-Diastolic Pressure in Impella 5.5.

作者: Reza Poyanmehr.;Jasmin S Hanke.;Dietmar Boethig.;Ali Saad Merzah.;Jan Karsten.;Paul Frank.;Martin Hinteregger.;Alina Zubarevich.;Günes Dogan.;Jan D Schmitto.;Andreas Schäfer.;L Christian Napp.;Aron Frederik Popov.;Alexander Weymann.;Johann Bauersachs.;Arjang Ruhparwar.;Bastian Schmack.
来源: Circ Heart Fail. 2025年18卷2期e012154页
Consensus regarding on-support evaluation and weaning concepts from Impella 5.5 support is scarce. The derived left ventricular end-diastolic pressure (dLVEDP), estimated by device algorithms, is a rarely reported tool for monitoring the weaning process. Its validation and clinical accuracy have not been studied in patients. We assess dLVEDP's accuracy in predicting pulmonary capillary wedge pressure (PCWP) and propose a corrective equation.

1262. Letter by Jha Regarding Article, "Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality".

作者: Ajay Kumar Jha.
来源: Circ Heart Fail. 2025年18卷2期e012511页

1263. Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP.

作者: Itsuki Osawa.;Keitaro Akita.;Kohei Hasegawa.;Michael A Fifer.;Albree Tower-Rader.;Muredach P Reilly.;Mathew S Maurer.;Nathan O Stitziel.;Ali Javaheri.;Yuichi J Shimada.
来源: Circ Heart Fail. 2025年18卷2期e012343页
Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and causes major adverse cardiovascular events (MACE). SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing 1) is a large extracellular matrix protein that is detectable in the plasma. However, it is unknown whether adding plasma SVEP1 levels to clinical predictors including NT-proBNP (N-terminal pro-B-type natriuretic peptide) improves the prognostication in patients with hypertrophic cardiomyopathy.

1264. Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations.

作者: Sushrima Gan.;Joe David Azzo.;Lei Zhao.;Bianca Pourmussa.;Marie Joe Dib.;Oday Salman.;Ozgun Erten.;Christina Ebert.;A Mark Richards.;Ali Javaheri.;Douglas L Mann.;Ernst Rietzschel.;Payman Zamani.;Vanessa van Empel.;Thomas P Cappola.;Julio A Chirinos.
来源: Circ Heart Fail. 2025年18卷2期e011728页
Iron deficiency (ID) is currently defined as a serum ferritin level <100 or 100 to 299 ng/mL with transferrin saturation (TSAT) <20%. Serum ferritin and TSAT are currently used to define absolute and functional ID. However, individual markers of iron metabolism may be more informative than current arbitrary definitions of ID.

1265. Pulseless Paradoxus: Pulsus Paradoxus of the 21st Century.

作者: Hadi Beaini.;Anas Jawaid.;Maryjane A Farr.;Faris G Araj.
来源: Circ Heart Fail. 2025年18卷4期e012657页

1266. Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies.

作者: Sarah-Eve Lemay.;Mónica S Montesinos.;Yann Grobs.;Tetsuro Yokokawa.;Tsukasa Shimauchi.;Manon Mougin.;Charlotte Romanet.;Mélanie Sauvaget.;Sandra Breuils-Bonnet.;Alice Bourgeois.;Charlie Théberge.;Andréanne Pelletier.;Reem El Kabbout.;Sandra Martineau.;Keiko Yamamoto.;Muzaffar Akram.;Adrian S Ray.;Blaise Lippa.;Bryan Goodwin.;Fu-Yang Lin.;Hua Wang.;James E Dowling.;Min Lu.;Qi Qiao.;T Andrew McTeague.;Terence I Moy.;François Potus.;Steeve Provencher.;Olivier Boucherat.;Sébastien Bonnet.
来源: Circulation. 2025年151卷16期1162-1183页
Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored.

1267. Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure.

作者: Micha T Maeder.;Frederik H Verbrugge.
来源: Circ Heart Fail. 2025年18卷2期e012675页

1268. Systemic Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review.

作者: Sara L Hungerford.;Kay D Everett.;Gaurav Gulati.;Kenji Sunagawa.;Daniel Burkhoff.;Navin K Kapur.
来源: Circ Heart Fail. 2025年18卷2期e012016页
The integrative physiology of the left ventricle and systemic circulation is fundamental to our understanding of advanced heart failure and cardiogenic shock. In simplest terms, any increase in aortic stiffness increases the vascular afterload presented to the failing left ventricle. The net effect is increased myocardial oxygen demand and reduced coronary perfusion pressure, thereby further deteriorating contractile function. Although mechanical circulatory support devices should theoretically work in concert with guideline-directed medical therapy, cardiac resynchronization and inotropic and vasopressor agents designed to support myocardial performance and enhance left ventricle recovery, this does not always occur. Each therapy and intervention may result in vastly different and sometimes deleterious effects on vascular afterload. Although best described by a combination of both steady-state and pulsatile components, the latter is frequently overlooked when mean arterial pressure or systemic vascular resistance alone is used to quantify vascular afterload in advanced heart failure and cardiogenic shock. In this state-of-the-art review, we examine what is known about vascular afterload in advanced heart failure and cardiogenic shock, including the use of temporary and permanent mechanical circulatory support systems. Importantly, we outline 4 key components for a more complete assessment of vascular afterload. Unlike previous discussions on this topic, we set aside considerations of venous return and ventricular preload, as important as they are, to focus exclusively on the hydraulic load within the systemic circulation against which the impaired left ventricle must contract.

1269. Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5.

作者: Matěj Běhounek.;Denisa Lipcseyová.;Ondřej Vít.;Petr Žáček.;Pavel Talacko.;Zuzana Husková.;Soňa Kikerlová.;Tereza Tykvartová.;Peter Wohlfahrt.;Vojtěch Melenovský.;Jan Beneš.;Jiří Petrák.
来源: Circ Heart Fail. 2025年18卷3期e011984页
Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis. However, no biomarker reflecting RVD is available for routine clinical use.

1270. RBM20 Gene in Patients With Cardiomyopathy: Phenotypic Expression for Loss-of-Function Versus Hotspot Variants.

作者: Alexis Hermida.;Flavie Ader.;Gilles Millat.;Guillaume Jedraszak.;Louis Vogel.;Loïc Garçon.;Philippe Maury.;Floriane Fay.;Christophe Beyls.;Anne-Claire Bréhin.;Laure Champ-Rigot.;Claire Dauphin.;Benjamin Dauriat.;Pascal De Groote.;Erwan Donal.;Delphine Dupin-Deguine.;Laurence Faivre.;Alexandre Janin.;Antoine Jobbe Duval.;Guillaume Jondeau.;Mikael Laredo.;Isabelle Magnin.;Eloi Marijon.;Karine Nguyen.;Aurélien Palmyre.;Alexandre Perani.;François Picard.;Patricia Reant.;Pascale Richard.;Caroline Rooryck.;François Roubille.;Cécile Rouzier.;Annick Toutain.;Agathe Vernier.;Pierre-François Winum.;Didier Scarlatti.;Frederic Sacher.;Momar Diouf.;Philippe Chevalier.;Philippe Charron.;Estelle Gandjbakhch.
来源: Circ Heart Fail. 2025年18卷3期e012492页

1271. Cave Under the Aortic Valve: The Rare Left Ventricular Outflow Tract Pseudoaneurysm With Thrombosis.

作者: Shuang Wang.;Wanwan Song.;Wenjun Yu.;Jinping Liu.;Bin Wang.
来源: Circ Cardiovasc Imaging. 2025年18卷6期e017574页

1272. Longitudinal Changes in Myocardial Deformation in Hutchinson-Gilford Progeria Syndrome.

作者: Flemming J Olsen.;Tor Biering-Sørensen.;Fatima I Lunze.;Sheila M Hegde.;Rachel Ehrbar.;Joseph Massaro.;Alessandra M Ferraro.;David M Harrild.;Monica E Kleinman.;Leslie B Gordon.;Ashwin Prakash.
来源: Circ Cardiovasc Imaging. 2025年18卷2期e017544页

1273. Development of an Innovative Decision-Aid to Better Align Patients' Implantable Cardioverter Defibrillator Shock Status With Goals of Care.

作者: Christine L Chen.;Sarah Godfrey.;Kelley Newcomer.;Kristin Alvarez.;Brenden Garrett.;Jingwen Zhang.;Nakul Patel.;Christopher Viamontes.;Nainesh Shah.;Nimesh S Patel.;Megan M Kelly.;Melanie S Sulistio.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e011544页

1274. Equitable Stroke Care for a Growing Population: The Need for Cultural Sensitivity.

作者: Patricia R Rodriguez-Lozano.;Cristiane C Singulane.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011737页

1275. Associations of Social, Behavioral, and Clinical Factors With Sex Differences in Stroke Recurrence and Poststroke Mortality.

作者: Chen Chen.;Mathew J Reeves.;Kevin He.;Lewis B Morgenstern.;Lynda D Lisabeth.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011082页
Few population-based studies have assessed sex differences in stroke recurrence. In addition, contributors to sex differences in recurrence and poststroke mortality, including social factors, are unclear. We investigated sex differences in these outcomes and the contribution of social, clinical, and behavioral factors to the sex differences.

1276. Examining Healthy Lifestyles as a Mediator of the Association Between Socially Determined Vulnerabilities and Incident Heart Failure.

作者: Nickpreet Singh.;Chanel Jonas.;Laura C Pinheiro.;Jennifer D Lau.;Jinhong Cui.;Leann Long.;Samprit Banerjee.;Raegan W Durant.;Madeline R Sterling.;James M Shikany.;Monika M Safford.;Emily B Levitan.;Parag Goyal.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e011107页
Increased burden of socially determined vulnerabilities (SDV), which include nonmedical conditions that contribute to patient health, is associated with incident heart failure (HF). Mediators of this association have not been examined. We aimed to determine if a healthy lifestyle mediates the association between SDV and HF.

1277. Medicare Coverage and Patient Out-of-Pocket Costs for Mavacamten.

作者: Kannu Bansal.;Christopher V Chien.;Ahmad Masri.;Ralph J Riello.;Tariq Ahmad.;Nihar R Desai.;Sourbha S Dani.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷2期e011331页

1278. Assessing and Addressing Cardiovascular and Obstetric Risks in Patients Undergoing Assisted Reproductive Technology: A Scientific Statement From the American Heart Association.

作者: Rina Mauricio.;Garima Sharma.;Jennifer Lewey.;Rose Tompkins.;Torie Plowden.;Kathryn Rexrode.;Mary Canobbio.;Jenna Skowronski.;Afshan Hameed.;Candice Silversides.;Harmony Reynolds.;Arthur Vaught.; .
来源: Circulation. 2025年151卷8期e661-e676页
The use of assisted reproductive technology (ART) is growing, both to assist individuals with infertility and for fertility preservation. Individuals with cardiovascular disease (CVD), or risk factors for CVD, are increasingly using ART. Thus, knowing how to care for patients undergoing ART is important for the cardiovascular clinician. In this scientific statement, we review the ART process and known short-term and long-term risks associated with ART that can adversely affect patients with CVD. We review current knowledge on risks from ART for specific cardiac conditions and provide a suggested approach to evaluating and counseling patients with CVD contemplating ART as well as suggested management before and during the ART process. Individuals with CVD are at increased risk for pregnancy complications, and management of this unique population has been discussed previously. The focus of this scientific statement is on ART. Therefore, discussions on risk assessment, counseling, and management of individuals with CVD during pregnancy are limited, and established guidelines are referenced.

1279. Determinants of Racial and Ethnic Differences in Maternal Cardiovascular Health in Early Pregnancy.

作者: Natalie A Cameron.;Xiaoning Huang.;Lucia C Petito.;Hongyan Ning.;Nilay S Shah.;Lynn M Yee.;Amanda M Perak.;David M Haas.;Brian M Mercer.;Samuel Parry.;George R Saade.;Robert M Silver.;Hyagriv N Simhan.;Uma M Reddy.;Jasmina Varagic.;Ernesto Licon.;Philip Greenland.;Donald M Lloyd-Jones.;Kiarri N Kershaw.;William A Grobman.;Sadiya S Khan.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e011217页
Suboptimal cardiovascular health (CVH) in pregnancy is associated with adverse maternal and offspring outcomes. To guide public health efforts to reduce disparities in maternal CVH, we determined the contribution of individual- and neighborhood-level factors to racial and ethnic differences in early pregnancy CVH.

1280. Cardiac Plasticity in Hypertrophic Cardiomyopathy: Exercise as Medicine?

作者: James P MacNamara.;Michael P Ayers.
来源: Circulation. 2025年151卷2期145-148页
共有 62504 条符合本次的查询结果, 用时 2.411655 秒